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 Norfloxacin, a new quinolinecarboxylic acid derivative, was administered to 30 male patients 
with gonococcal urethritis at a daily dose of 600 mg for 7-21 days. The clinical response was 
evaluated after administration of 7 days as excellent; Negative culture of N. gonorrhoeae. WBC<3/
hpf in first voided urine sediment, good; Negative culture, WBC>3/hpf, and poor; Positive cul-
ture. 
   The result was excellent in 14 cases and good in 16 cases. No subjective side effects were
observed. The minimum inhibitory concentration (MIC) distribution against the clinically isolated 
30 strains of N. gonorrhoeae ranged from 0.0096 jug/m1 to 0.34 fig/ml. Seven of thirty strains were
resistant o ABPC. The MIC of these 7 strains ranged from 0.018 pg/ml to 0.18 yg/ml. 
   Seven cases with ABPC resistant strains had a similar clinical response to other cases. Twelve 
patients (40%) developed post gonococcal urethritis for 7-14 days after treatment.
Clinical observation of this series suggests that a 7 day therapy of Norfloxacin for the patients
with gonococcal urethritis is sufficiently effective and that treatment should be changed to other 
antibacterial agents in the case of post gonococcal urethritis, since continuous administration for 
more than 7 days of Norfloxacin is not so effective.































































































































































































































































































































































尿道スミア中の淋菌培養を施行し,初 尿沈渣中 の 白
血球数 を検 した.そ の後は,経 過に よ りNFLX


























16例(53%),無効 な し とい う結 果 で あ った.自 覚症
状 は,4例 を 除 い て 消失 した.自 覚 症 状 消 失 に は,ほ
とん ど の症 例 で4～2日 を要 した.全 患 老 よ り分離 した
N.gonorrhoeae30株に つ いてMICを 測 定 した と こ
ろo・oo96Pt9/ml～o.34μ9/m王と良 好 な 値 を示 した.
尚,7例(23%)にABPC耐 性 菌 が 認 め られ た が臨
床 効 果 は著 効5例,有 効2例 と良 好 で あ った.こ れ ら
7株 のMIG値 は,o.018μ9/ml～o.18μ9/mlであ
った.PGUは,2週 間 目 まで の経 過 で12例(40%)







































































































場合PGUと 推定して よい と考えられた.こ れらの
PGUの 症例ではN肌Xの 効果は今一つであり,




方NFLX2週 投与例 で,2週 目以降にPGUの
表面化したケースが2例(case8,20)あり,こ れは







わが国におけ る淋疾治療 の現況 は不 明な点 も多























PGUと 推定され,PGUは40%の 症例 にみ られ
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